Professor Louise Bowman
BA, MBBS, MD, FRCP
Professor of Medicine & Clinical Trials, and Honorary Consultant Physician (Lipidology)
- Clinical Trial Service Unit
- MRC PHRU Programme Leader
Louise Bowman is Professor of Medicine and Clinical Trials at the Clinical Trial Service Unit of the University of Oxford. Her specialist clinical background is in Diabetes and Endocrinology. She has particular research interests in cardiovascular disease in diabetes, and maintains her clinical practice with regular specialist lipid clinics. She is Chief Investigator for the ORION-4 trial which will assess the effects of inclisiran on clinical outcomes among 15,000 people with atherosclerotic cardiovascular disease, and for the AMALFI trial, which will assess the value of screening for undiagnosed atrial fibrillation in high-risk individuals.
Prof Bowman is also Co-principal Investigator for the recently-reported ASCEND trial, which studied the effects of aspirin and of omega-3 fatty acid supplementation for the primary prevention of cardiovascular disease in 15,000 people with diabetes, and for the REVEAL study, an international clinical trial that assessed the efficacy and safety of the CETP-inhibitor, anacetrapib, in 30,000 high-risk individuals.
Through her work on large-scale trials in cardiovascular disease she has developed a specialist interest in Clinical Trials Methodology and is Director of the Oxford CTSU Hub for the MRC Network of Hubs for Trials Methodology Research (HTMR). Her focus is on the development, application and widespread promotion of methods to enhance the design and conduct of trials to ensure high quality outputs and reliable results at low cost.
Assessement of Vascular Event Prevention and Cognitive Function Among Older Adults With Preexisting Vascular Disease or Diabetes: A Secondary Analysis of 3 Randomized Clinical Trials.
Offer A. et al, (2019), JAMA Netw Open, 2
Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
ASCEND Study Collaborative Group None. et al, (2018), N Engl J Med, 379, 1529 - 1539
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
ASCEND Study Collaborative Group None. et al, (2018), N Engl J Med, 379, 1540 - 1550
Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.
Haynes R. et al, (2018), Circulation, 138, 1505 - 1514
Post-trial follow-up methodology in large randomised controlled trials: a systematic review.
Llewellyn-Bennett R. et al, (2018), Trials, 19